Management with colistin
2010
Management with Colistin
publication
Author Information
Author(s): Gupta Sachin, Govil Deepak, Kakar Prem N., Prakash Om, Arora Deep, Das Shibani, Govil Pradeep, Malhotra Ashima
Primary Institution: Max Super Speciality Hospital
Conclusion
Colistin is becoming a standard adjuvant therapy for Ventilator Associated Pneumonia with lower toxicity than previously reported.
Supporting Evidence
- Colistin is resistant to certain bacterial species.
- Aerosolization of colistin is becoming standard for treating lung infections.
- Bronchospasm is less common than previously thought when using colistin.
- Recent literature shows colistin has lower toxicity than older reports.
Takeaway
Colistin can help treat lung infections in patients on ventilators, and it seems to be safer now than it used to be.
Methodology
Colistin is administered through ultrasonic nebulizers to maximize lung concentration.
Potential Biases
Theoretical neurological side effects are mentioned, but recent data suggest lower toxicity.
Limitations
No data are available for dose adjustment for nebulization in renal disease.
Want to read the original?
Access the complete publication on the publisher's website